Published in Nat Genet on March 07, 2016
Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell (2016) 0.90
Defining the clonal dynamics leading to mouse skin tumour initiation. Nature (2016) 0.88
Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling. Oncotarget (2016) 0.77
Aurora kinase-A overexpression in mouse mammary epithelium induces mammary adenocarcinomas harboring genetic alterations shared with human breast cancer. Carcinogenesis (2016) 0.77
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. J Immunother Cancer (2016) 0.77
High-Risk Human Papillomavirus E7 Proteins Target PTPN14 for Degradation. MBio (2016) 0.76
The Regulatory Role of KIBRA and PTPN14 in Hippo Signaling and Beyond. Genes (Basel) (2016) 0.76
MYC Deregulation in Primary Human Cancers. Genes (Basel) (2017) 0.75
Hedgehog signaling in the stomach. Curr Opin Pharmacol (2016) 0.75
Biallelic Alteration and Dysregulation of the Hippo Pathway in Mucinous Tubular and Spindle Cell Carcinoma of the Kidney. Cancer Discov (2016) 0.75
Tumor-Derived Suppressor of Fused Mutations Reveal Hedgehog Pathway Interactions. PLoS One (2016) 0.75
Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium. Carcinogenesis (2016) 0.75
SNooPer: a machine learning-based method for somatic variant identification from low-pass next-generation sequencing. BMC Genomics (2016) 0.75
Genetic alterations in seborrheic keratoses. Oncotarget (2017) 0.75
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. J Immunother Cancer (2017) 0.75
Skin Cancer Epidemics in the Elderly as An Emerging Issue in Geriatric Oncology. Aging Dis (2017) 0.75
The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ (2017) 0.75
Decreased expression of the mitochondrial solute carrier SLC25A43 in basal cell carcinoma compared with healthy skin. Oncol Lett (2017) 0.75
Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics (2009) 190.94
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc (2009) 137.99
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res (2008) 54.83
Cancer genome landscapes. Science (2013) 25.33
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature (2013) 20.16
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature (2002) 15.36
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Discovery and saturation analysis of cancer genes across 21 tumour types. Nature (2014) 11.68
Integrative analysis of 111 reference human epigenomes. Nature (2015) 10.32
Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J Mol Biol (2002) 9.74
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol (2011) 9.60
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55
FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer (2008) 7.93
Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90
Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci (2007) 5.81
Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature (2015) 5.50
Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem (2007) 5.49
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
Yap1 acts downstream of α-catenin to control epidermal proliferation. Cell (2011) 4.85
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Scalable web services for the PSIPRED Protein Analysis Workbench. Nucleic Acids Res (2013) 4.24
Genomic Classification of Cutaneous Melanoma. Cell (2015) 3.91
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science (2013) 3.45
TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition. J Biol Chem (2009) 3.20
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2011) 3.10
Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol (2009) 3.01
Identification of the cell lineage at the origin of basal cell carcinoma. Nat Cell Biol (2010) 2.97
Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol (1992) 2.85
Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta Neuropathol (2011) 2.82
KinasePhos 2.0: a web server for identifying protein kinase-specific phosphorylation sites based on sequences and coupling patterns. Nucleic Acids Res (2007) 2.69
Hedgehog regulates cell growth and proliferation by inducing Cyclin D and Cyclin E. Nature (2002) 2.40
Impact of replication timing on non-CpG and CpG substitution rates in mammalian genomes. Genome Res (2010) 2.37
The eukaryotic linear motif resource ELM: 10 years and counting. Nucleic Acids Res (2013) 2.25
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proc Natl Acad Sci U S A (2011) 2.08
c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood (2000) 2.08
Smoothened variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell (2015) 2.03
Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol (2005) 1.90
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell (2015) 1.73
Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions. Sci Signal (2013) 1.69
Mutant p53: an oncogenic transcription factor. Oncogene (2007) 1.62
UV signature mutations. Photochem Photobiol (2014) 1.52
Repair and transcription. Collision or collusion? Curr Biol (1994) 1.50
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification. Proc Natl Acad Sci U S A (2012) 1.46
Aberrant activation, nuclear localization, and phosphorylation of Yes-associated protein-1 in the embryonic kidney and Wilms tumor. Pediatr Blood Cancer (2013) 1.46
Chromosome 6p amplification and cancer progression. J Clin Pathol (2006) 1.42
Mutational landscape of basal cell carcinomas by whole-exome sequencing. J Invest Dermatol (2013) 1.38
Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol (2012) 1.36
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial. Lancet Oncol (2015) 1.35
Function of the c-Myc oncoprotein. FASEB J (1992) 1.34
Neural precursor cycling at sonic speed: N-Myc pedals, GSK-3 brakes. Cell Cycle (2006) 1.34
Genome-wide analysis of human global and transcription-coupled excision repair of UV damage at single-nucleotide resolution. Genes Dev (2015) 1.28
Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle (2007) 1.27
PTPN14 is required for the density-dependent control of YAP1. Genes Dev (2012) 1.23
Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet (2014) 1.20
Mutual interaction between YAP and c-Myc is critical for carcinogenesis in liver cancer. Biochem Biophys Res Commun (2013) 1.17
Recurrent point mutations in the kinetochore gene KNSTRN in cutaneous squamous cell carcinoma. Nat Genet (2014) 1.09
edgeR for differential RNA-seq and ChIP-seq analysis: an application to stem cell biology. Methods Mol Biol (2014) 1.06
The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics. J Am Acad Dermatol (2010) 1.06
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet (2015) 1.05
Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol (2014) 1.02
Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg (2010) 1.00
Melanoma-associated mutations in protein phosphatase 6 cause chromosome instability and DNA damage owing to dysregulated Aurora-A. J Cell Sci (2013) 0.98
MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma. Nucleic Acids Res (2013) 0.98
Gene expression profiling of the hedgehog signaling pathway in human meningiomas. Mol Med (2010) 0.97
MEK1 promotes YAP and their interaction is critical for tumorigenesis in liver cancer. FEBS Lett (2013) 0.94
Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol (1999) 0.94
Riboflavin activated by ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations inhibited by vitamin C. Proc Natl Acad Sci U S A (2007) 0.94
Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist (2014) 0.92
Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget (2015) 0.91
PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J Biol Chem (2014) 0.90
Sonic Hedgehog pathway is essential for neuroblastoma cell proliferation and tumor growth. Mol Cell Biochem (2012) 0.89
Extrachromosomal driver mutations in glioblastoma and low-grade glioma. Nat Commun (2014) 0.88
New basal cell carcinoma susceptibility loci. Nat Commun (2015) 0.87
Frequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations. Nat Commun (2014) 0.84
Characteristics of UV-induced mutation spectra in human XP-D/ERCC2 gene-mutated xeroderma pigmentosum and trichothiodystrophy cells. J Mol Biol (1995) 0.83
UV-induced G:C-->A:T transitions at the APRT locus of Chinese hamster ovary cells cluster at frequently damaged 5'-TCC-3' sequences. Mutat Res (1993) 0.79
Mutations in the Kinetochore Gene KNSTRN in Basal Cell Carcinoma. J Invest Dermatol (2015) 0.78
Recurrent NMYC copy number gain and high protein expression in basal cell carcinoma. Oncol Rep (2006) 0.78
Biallelic alterations of the large tumor suppressor 1 (LATS1) gene in infiltrative, but not superficial, basal cell carcinomas in a Japanese patient with nevoid basal cell carcinoma syndrome. Med Mol Morphol (2014) 0.76
A MYC-aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nat Med (2016) 1.47
Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration. Stem Cells (2015) 0.80
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors. Oncogene (2016) 0.77
Exome sequencing discloses KALRN homozygous variant as likely cause of intellectual disability and short stature in a consanguineous pedigree. Hum Genomics (2016) 0.77
HSA21 Single-Minded 2 (Sim2) Binding Sites Co-Localize with Super-Enhancers and Pioneer Transcription Factors in Pluripotent Mouse ES Cells. PLoS One (2015) 0.75
Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma. EMBO Mol Med (2017) 0.75
MYC and tumor metabolism: chicken and egg. EMBO J (2017) 0.75
The MYC mRNA 3'-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. EMBO J (2017) 0.75
Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases. Mol Cancer Ther (2016) 0.75